---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-012131"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:17:04.186237+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Monopar files provisional patent for MNPR-101 radiopharma optimization findings

## Summary
- Filed provisional patent 'Antibody Radioisotope Constructs' covering MNPR-101-Zr construct, including radioisotope, linker, and antibody variations.
- Patent aims to protect stability and biodistribution properties of MNPR-101-Zr.
- MNPR-101-Zr is a zirconium-89 imaging version of Monopar's anti-uPAR antibody for advanced cancers.
- Filing strengthens IP for MNPR-101 radiopharma program; Phase 1 dosimetry trial recently initiated.

## SEC filing metadata
- accession: 0001437749-24-012131
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924012131/0001437749-24-012131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924012131/mnpr20240415_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-012131
- JSON: https://secwatch.observer/filing/0001437749-24-012131.json
- Plain text: https://secwatch.observer/filing/0001437749-24-012131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.